CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Down 12.4% in June

CytoDyn Inc. (OTCMKTS:CYDY) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 7,062,000 shares, a decline of 12.4% from the May 31st total of 8,060,300 shares. Based on an average daily volume of 8,485,300 shares, the days-to-cover ratio is currently 0.8 days.

CytoDyn Price Performance

Shares of CYDY stock remained flat at $0.14 during trading on Monday. 670,333 shares of the company were exchanged, compared to its average volume of 2,718,123. CytoDyn has a 12 month low of $0.13 and a 12 month high of $0.42. The company has a market capitalization of $139.14 million, a P/E ratio of -2.75 and a beta of 0.21. The stock has a 50-day moving average price of $0.16 and a 200-day moving average price of $0.17.

CytoDyn (OTCMKTS:CYDY) last issued its earnings results on Monday, April 15th. The biotechnology company reported ($0.01) EPS for the quarter.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.